Evan N Cohen
Overview
Explore the profile of Evan N Cohen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1998
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iwase T, Parikh A, Wenli D, Shen Y, Adams D, Tang C, et al.
J Cancer
. 2024 Oct;
15(18):5855-5862.
PMID: 39440056
Cancer-associated macrophage-like cells (CAMLs) are rare, gigantic, and atypical circulating cells found exclusively in the peripheral blood of patients with solid cancers. Obesity-induced hypoxia attracts macrophages to the tumor microenvironment,...
2.
Iwase T, Cohen E, Gao H, Alexander A, Kai M, Chiv V, et al.
Clin Cancer Res
. 2024 Apr;
30(11):2424-2432.
PMID: 38629963
Purpose: Accumulating toxicities hinder indefinite chemotherapy for many patients with metastatic/recurrent HER2-negative breast cancer. We conducted a phase II trial of pembrolizumab monotherapy following induction chemotherapy to determine the efficacy...
3.
Qiu L, Lin P, Khanlari M, Xu J, Cohen E, Garces S, et al.
Mod Pathol
. 2023 Oct;
36(12):100349.
PMID: 37820764
A small subset of high-grade B-cell lymphoma (HGBL) with blastoid morphology remains poorly understood. We assessed 55 cases of blastoid HGBL, not otherwise specified (NOS) and compared their clinicopathologic characteristics...
4.
Cohen E, Jayachandran G, Gao H, Peabody P, McBride H, Alvarez F, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900406
Circulating tumor cells (CTCs) are indicators of metastatic spread and progression. In a longitudinal, single-center trial of patients with metastatic breast cancer starting a new line of treatment, a microcavity...
5.
Cohen E, Jayachandran G, Gao H, Peabody P, McBride H, Alvarez F, et al.
Transl Lung Cancer Res
. 2023 Feb;
12(1):109-126.
PMID: 36762061
Background: Circulating tumor cells (CTCs) are a promising non-invasive tool for monitoring therapy response. The only Food and Drug Administration (FDA)-approved test is limited to enumeration of epithelial CTC without...
6.
Wang X, Semba T, Manyam G, Wang J, Shao S, Bertucci F, et al.
Sci Adv
. 2022 Dec;
8(50):eabn7983.
PMID: 36525493
Inflammatory breast cancer (IBC), the most aggressive breast cancer subtype, is driven by an immunosuppressive tumor microenvironment (TME). Current treatments for IBC have limited efficacy. In a clinical trial (NCT01036087),...
7.
Cohen E, Jayachandran G, Moore R, Cristofanilli M, Lang J, Khoury J, et al.
Cancers (Basel)
. 2022 Nov;
14(21).
PMID: 36358657
Circulating tumor cells (CTCs) captured from the blood of cancer patients may serve as a surrogate source of tumor material that can be obtained via a venipuncture (also known as...
8.
Qiu L, Xu J, Lin P, Cohen E, Tang G, Wang S, et al.
Haematologica
. 2022 Nov;
108(3):895-899.
PMID: 36325892
No abstract available.
9.
Wu L, Dai P, Wang M, Chen S, Cohen E, Jayachandran G, et al.
Nat Commun
. 2022 Apr;
13(1):1791.
PMID: 35379811
Current gold standard for absolute quantitation of a specific DNA sequence is droplet digital PCR (ddPCR), which has been applied to copy number variation (CNV) detection. However, the number of...
10.
Semba T, Wang X, Xie X, Cohen E, Reuben J, Dalby K, et al.
J Natl Cancer Inst
. 2021 Jul;
114(1):97-108.
PMID: 34250544
Background: Although an immunosuppressive tumor microenvironment (TME) is key for tumor progression, the molecular characteristics associated with the immunosuppressive TME remain unknown in triple-negative breast cancer (TNBC). Our previous functional...